Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Low Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06957886
What this trial is testing

BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Who this might be right for
HER2-low Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 566
Not applicableLooking for participantsNCT06727227
What this trial is testing

Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 138
Testing effectiveness (Phase 2)Study completedNCT00900627
What this trial is testing

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

Who this might be right for
NeoplasmsBreast NeoplasmsBreast Cancer
AstraZeneca 330
Testing effectiveness (Phase 2)UnknownNCT05749575
What this trial is testing

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Who this might be right for
Breast Cancer
Sun Yat-sen University 28
Testing effectiveness (Phase 2)Ended earlyNCT02115048
What this trial is testing

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Who this might be right for
Breast Neoplasms
Translational Research in Oncology 44
Testing effectiveness (Phase 2)Looking for participantsNCT07383818
What this trial is testing

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

Who this might be right for
HR Positive/HER2 Low Breast Cancer
First Affiliated Hospital of Zhejiang University 111
Testing effectiveness (Phase 2)Study completedNCT02048059
What this trial is testing

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Who this might be right for
Breast CancerBrain Metastases
Angiochem Inc 72
Testing effectiveness (Phase 2)Looking for participantsNCT07380646
What this trial is testing

The Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer

Who this might be right for
LeucogenRibociclibNeutropenia (Low White Blood Cell Count)+1 more
Second Affiliated Hospital, Zhejiang University, School of Medicine 94
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592625
What this trial is testing

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

Who this might be right for
Untreated Early-stage or Locally Advanced Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 60
Not applicableLooking for participantsNCT06813456
What this trial is testing

Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype

Who this might be right for
Breast Cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna 234
Testing effectiveness (Phase 2)UnknownNCT05018676
What this trial is testing

ARX788 in Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer With Low Expression of HER2
Fudan University 54
Large-scale testing (Phase 3)Looking for participantsNCT05904964
What this trial is testing

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Who this might be right for
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 288
Early research (Phase 1)Looking for participantsNCT05504707
What this trial is testing

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 30
Not applicableStudy completedNCT06386263
What this trial is testing

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
AstraZeneca 22
Not applicableLooking for participantsNCT07597993
What this trial is testing

BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy

Who this might be right for
Breast Cancer
AstraZeneca 109
Testing effectiveness (Phase 2)Looking for participantsNCT07678957
What this trial is testing

A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 120
Early research (Phase 1)Active Not RecruitingNCT01351909
What this trial is testing

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced Unresectable Breast CarcinomaMetastatic Breast CarcinomaRecurrent Breast Carcinoma+3 more
National Cancer Institute (NCI) 35
Not applicableEnded earlyNCT05592483
What this trial is testing

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 78
Large-scale testing (Phase 3)Active Not RecruitingNCT06018337
What this trial is testing

DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Who this might be right for
Metastatic Breast Cancer
DualityBio Inc. 541
Testing effectiveness (Phase 2)Looking for participantsNCT07796880
What this trial is testing

Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHER2 Low Breast CarcinomaEarly-Stage Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 80
Next Page